Pheochromocytoma, Paraganglioma
Conditions
Keywords
Pheochromocytoma, Paraganglioma, MIBG, 131I-MIBG, Resistant, Relapsed, Treatment, UCSF, Pediatric, Adult, Oncology
Brief summary
This is an ongoing prospective Phase II clinical trial evaluating the efficacy of 131I-MIBG for the treatment of patients with metastatic or unresectable pheochromocytoma and related tumors.
Detailed description
1. To assess the efficacy of high-dose 131I-MIBG in the treatment of patients with malignant pheochromocytoma and related tumors, with the basis of this initial examination being the percentage of patients in CR or PR, and the percentage of patients without PD for 3 years after the initial administration on 131I-MIBG therapy. 2. To describe the response rate of malignant pheochromocytoma patients treated with high-dose 131I-MIBG. 3. To describe the toxicity of high-dose 131I-MIBG in patients with malignant pheochromocytoma. 4. To describe the overall survival and failure-free survival of malignant pheochromocytoma patients treated with high-dose 131I-MIBG. 5. To determine the utility of using the serum level of Chromogranin A as a tumor marker for patients with malignant pheochromocytoma.
Interventions
RADIATION131I-MIBG
Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
Sponsors
University of California, San Francisco
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic Documentation: Histologic documentation of malignant pheochromocytoma or related tumors (paraganglioma, neuroblastoma, medullary thyroid carcinoma, carcinoid tumors), not amenable to curative surgery. Any site of origin of malignant pheochromocytoma, including but not limited to: adrenal, neck, thorax, abdominal, or pelvis is allowed. * Prior Treatment: * No cytotoxic chemotherapy for at least 3 weeks prior to high-dose 131I-MIBG or concurrent with high-dose 131I-MIBG. * \> 2 weeks since major surgery. * \> 4 weeks since completion of prior radiation therapy, as long as measurable disease lies outside the radiation port. * No treatment with an investigational agent concurrent or within 30 days of high-dose 131I-MIBG. * Patients who have received previous chemotherapy or radiation therapy must have evidence of persistent disease on 123I-MIBG scan and elevated tumor markers or measurable CT lesions before receiving high-dose 131I-MIBG. * Metastases Excluding Eligibility: No patients with a known significant MIBG-avid parenchymal brain metastasis; leptomeningeal metastases do not exclude eligibility. Hepatic metastases exclude eligibility if they functionally impair liver function (AST or total bilirubin ≥ 2.5 times the ULN). * Measurable Disease Lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 10 mm as measured with CT scanning. Lesions \< 10 mm diameter or bone lesions in the presence of demonstrable uptake of 123I-MIBG on diagnostic scanning, plus elevated levels of tumor markers that are specific for malignant pheochromocytoma: plasma catecholamines or metanephrines, urine catecholamines or metanephrines, serum chromogranin A. Lesions whose size is considered non-measurable include the following: * Bone lesions (see above) * Leptomeningeal disease * Ascites * Pleural/pericardial effusion * Chylothorax * Lesions within the chest or abdomen that are not confirmed to be pheochromocytoma by biopsy or 123I-MIBG scanning. * 131I-MIBG or 123I-MIBG Avidity: All patients must have 123I-MIBG or 131I-MIBG whole-body scanning prior to therapy. Metastases must be avid for the isotope such that their measured gamma radiation measures ≥ twice that of background radiation. * Subsequent 131I-MIBG Therapies: Patients must have had pain relief or a SD or PR after a prior therapy to be eligible for another therapy. Patients with PD within 9 months of the prior therapy are excluded from receiving subsequent therapy. * Age: ≥4 years of age. * Life Expectancy: greater than 9 months. * Karnofsky Performance Status: 70% or higher. * Anticoagulation: Heparin, LMW heparin, coumadin, and other anticoagulants may be used only when platelet counts are ≥ 100,000/micronL. Platelet counts will be monitored twice weekly after 131I-MIBG therapy. * Pregnancy & Nursing: Non-pregnant and non-nursing because the effects of high-dose 131I-MIBG on the fetus/infant are unknown. * Second Malignancies: * Patients with a currently active second malignancy, other than non-melanoma skin cancers, are not eligible. * Patients are not considered to have a currently active second malignancy if they have been cancer-free for ≥5 years. * Intercurrent Illness: No patients with uncontrolled intercurrent illness including but not limited to: ongoing active infections, grade 3 or 4 congestive heart failure by echocardiogram, nephrotic syndrome, serum albumin \< 3, significant ascites or pleural effusion, pulmonary function testing (FVC) less than 70% of predicted for age, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Required Initial Laboratory Data (Minimum Levels): * Neutrophil count \>/= 1,000/micronL * Platelet count \>/= 80,000/micronL * AST (SGOT) ≤ 2.5 x ULN * Total bilirubin ≤ 2.5 x ULN * Creatinine ≤ 2 x ULN
Exclusion criteria
* 1\) Pregnancy & Nursing: Non-pregnant and non-nursing because the effects of high-dose 131I-MIBG on the fetus/infant are unknown. * 2\) Second Malignancies: * Patients with a currently active second malignancy, other than non-melanoma skin cancers, are not eligible. * Patients are not considered to have a currently active second malignancy if they have been cancer-free for ≥5 years * 3\) Intercurrent Illness: No patients with uncontrolled intercurrent illness including but not limited to: ongoing active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Complete (CR), Partial (PR), or Minor (MR) Response and Without Progressive Disease | After 1 year from initial treatment | Patients with complete (CR), partial (PR), or minor (MR) response and without progressive disease 1 year from initial treatment, using RECIST RESPONSE CRITERIA for measurable soft tissue tumor: CR=No Tumor (Primary or metastatic); catacholamines, metanephrines and chromogranin A all normal. PR=Primary and all measurable sites decreased \>50%; number of positive bone sites decreased by \>50%; bone marrow tumor decreased by 50%. MR=No new lesions; \>50% reduction of any measurable lesion (primary or metastases); \<25% increase in any existing lesion. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 131I-MIBG Patients received 131I-MIBG infused intravenously through a peripheral or central line over 120 minutes.
Of 50 patients enrolled and treated, one patient was lost to follow-up. | 49 |
| Total | 49 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 1 |
Baseline characteristics
| Characteristic | 131I-MIBG |
|---|---|
| Age, Continuous | 42.6 years |
| Region of Enrollment United States | 49 participants |
| Sex: Female, Male Female | 20 Participants |
| Sex: Female, Male Male | 29 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 49 |
| other Total, other adverse events | 43 / 49 |
| serious Total, serious adverse events | 6 / 49 |
Outcome results
Primary
Number of Patients With Complete (CR), Partial (PR), or Minor (MR) Response and Without Progressive Disease
Patients with complete (CR), partial (PR), or minor (MR) response and without progressive disease 1 year from initial treatment, using RECIST RESPONSE CRITERIA for measurable soft tissue tumor: CR=No Tumor (Primary or metastatic); catacholamines, metanephrines and chromogranin A all normal. PR=Primary and all measurable sites decreased \>50%; number of positive bone sites decreased by \>50%; bone marrow tumor decreased by 50%. MR=No new lesions; \>50% reduction of any measurable lesion (primary or metastases); \<25% increase in any existing lesion.
Time frame: After 1 year from initial treatment
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 131I-MIBG | Number of Patients With Complete (CR), Partial (PR), or Minor (MR) Response and Without Progressive Disease | 28 Participants |